Applied Clinical Trials Announces First Annual Clinical Trials Outsourcing Quality Assessment - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Applied Clinical Trials Announces First Annual Clinical Trials Outsourcing Quality Assessment

Source: Applied Clinical Trials

Responding to growing interest in clinical trial outsourcing quality and solutions, Applied Clinical Trials announced today the first comprehensive in-depth analysis of the quality of outsourced clinical research. The groundbreaking research project will survey sponsor managers and executives involved to determine their view of the state of the outsourcing industry that continues to grow even faster than overall clinical research.

Applied Clinical Trials will collaborate with CRO Analytics on the project, utilizing its PerformerTM platform to collect the data. CRO Analytics’ Chief Scientific Officer Dr. Michael Howley will lead the analysis and reporting of results.

Said Lisa Henderson, Applied Clinical Trials Editor-in-Chief, “Perhaps more than any other topic clinical trial outsourcing solutions are of constant interest to our readers. The environment is evolving so rapidly that we thought it important to step back and assess where it stands in a comprehensive manner.”  Added, Henderson, “The research will help us establish a baseline that can be revisited in the future to as well as provide a robust data set that will enable us to drill down and report on key drivers of clinical research quality.”

Current sponsor personnel will be invited to register for the project beginning the week of June 9. Once registered, they will be able to select any active or recently completed Phase II-IV trial from the clinicltrials.gov listings to assess.

Participants can then choose from five assessments (Sales and Contracting, Study Start-Up, Study Conduct, Study Close-Out, and Overall Performance) and may complete as many assessments for as many trials as they are qualified. All participants will remain anonymous but will be confirmed as sponsor personnel and all results will be aggregated. No individual sponsors, trials, or research service providers identified.

Explained Henderson, “The intent is to take stock of where we are as an industry—not to call out or measure individual organizations. We’re excited about this because nobody has really looked at outsourcing quality in such a holistic, rigorous fashion before.”

Peter Malamis, CEO of CRO Analytics said the company was honored to be part of the effort, “Our team has put a lot of time over the last three years developing Performer. Our statistically validated assessments and cloud-based platform are uniquely suited for this type of research and we look forward to helping Applied Clinical Trials provide an important new perspective on this critical area.”

To learn more, please visit www.appliedclinicaltrialsonline.com or www.croanalytics.com.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here